Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlorpropamide
Drug ID BADD_D00447
Description Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Indications and Usage For treatment of NIDDM in conjunction with diet and exercise.
Marketing Status approved; investigational
ATC Code A10BB02
DrugBank ID DB00672
KEGG ID D00271
MeSH ID D002747
PubChem ID 2727
TTD Drug ID D00BCP
NDC Product Code 52537-004
UNII WTM2C3IL2X
Synonyms Chlorpropamide | Clorpropamid | Diabinese | Insogen | Apo-Chlorpropamide | Glucamide | Meldian
Chemical Information
Molecular Formula C10H13ClN2O3S
CAS Registry Number 94-20-2
SMILES CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agranulocytosis01.02.03.001---
Alcohol intolerance14.02.01.001--
Aplastic anaemia01.03.03.002---
Asthenia08.01.01.001---
Blood osmolarity decreased13.11.02.005---
Colitis07.08.01.001--
Dermatitis23.03.04.002---
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug interaction08.06.03.001---
Dyspepsia07.01.02.001--
Eosinophilia01.02.04.001--
Erythema multiforme10.01.03.015; 23.03.01.003--
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Fluid retention14.05.06.002; 20.01.02.003---
Gastrointestinal disorder07.11.01.001---
Haemolytic anaemia01.06.03.002---
Headache17.14.01.001--
Hepatitis09.01.07.004---
Hepatitis cholestatic09.01.01.002---
Hunger08.01.09.003; 14.03.02.012---
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Jaundice cholestatic09.01.01.005---
Leukopenia01.02.02.001---
Nausea07.01.07.001--
Pancytopenia01.03.03.003---
The 1th Page    1 2    Next   Last    Total 2 Pages